MAQBOOL AHMED
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology CLARKSVILLE, TN NPI 1548300916
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology TN Lilly USA, LLC All categories
General Payments — all program years on this page
$7,715.81
- Category: General Payments
- Program years: PY2018–2024
- Record count: 278
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,505.93 across 58 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,505.93 | 58 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $171.75 | 4 |
| EISAI INC. | $150.92 | 3 |
| Biogen, Inc. | $136.24 | 6 |
| SK Life Science, Inc. | $129.58 | 4 |
| Alexion Pharmaceuticals, Inc. | $90.93 | 3 |
| TG THERAPEUTICS, INC. | $74.27 | 3 |
| ABBVIE INC. | $70.30 | 3 |
| Genentech USA, Inc. | $62.09 | 3 |
| Acerta Pharma LLC | $58.93 | 2 |
| UCB, Inc. | $57.97 | 2 |
| JAZZ PHARMACEUTICALS INC. | $54.94 | 2 |
| Amneal Pharmaceuticals LLC | $54.60 | 3 |
| Sumitomo Pharma America, Inc. | $45.77 | 3 |
| Lundbeck LLC | $39.66 | 2 |
| EMD Serono, Inc. | $35.97 | 2 |
| LivaNova USA, Inc. | $32.18 | 1 |
| Grifols USA, LLC | $30.23 | 1 |
| ANI Pharmaceuticals, Inc. | $27.49 | 1 |
| ARGENX US, INC. | $27.02 | 1 |
| CYCLE PHARMACEUTICALS INC | $23.13 | 1 |
| Vanda Pharmaceuticals Inc. | $20.57 | 1 |
| Teva Pharmaceuticals USA, Inc. | $18.24 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $17.57 | 1 |
| Merz Pharmaceuticals, LLC | $17.40 | 1 |
| PFIZER INC. | $16.84 | 1 |
| Neurelis, Inc. | $14.14 | 1 |
| ACADIA Pharmaceuticals Inc | $14.12 | 1 |
| Neurocrine BioSciences, Inc. | $13.08 | 1 |
By program year
Records — PY2024 (58)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.